Oncolytic Viral Therapy
Oncolytic virus therapy is a class of immunotherapy that preferentially kills cancer cells by oncolysis and may also stimulate host anti-tumor immune system responses.
With advances in cancer immunotherapy, increased attention has been given to using oncolytic viruses to increase anti-tumor immunity.
WHY ARE ONCOLYTIC VIRUSES IMPORTANT?
Oncolytic viral therapy is a class of immunotherapy that provides the ability to directly target tumor cells and the opportunity to harness a patient’s immune system to kill tumor cells, although there are still significant hurdles to overcome. Transductional targeting modifies the viral coat protein to target tumor cells and reduce non-specific effects, whilst transcriptional targeting switches critical parts of the viral genome under the control of a tumor-specific promoter. Placing reporter genes such as Green Fluorescent Protein (GFP) enables the quantification of infectivity, penetration and replication of the virus.
Nilogen’s 3D-EXplore platform enables the direct measurement of oncolytic virus therapy to penetrate the tumor, infect tumor cells and replicate, whilst determining the impact on the immune population in the tumor microenvironment.
Capabilities
SCIENTIFIC DATA
Related Resources
Browse our latest posters and presentations using Nilogen's fresh patient tumoroid technology.